Multi-dimensional QSAR in drug discovery

Drug Discovery Today

Volumn 12, Issue 23-24, 2007, Pages 1013-1017

  Lill, Markus A ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; RALOXIFENE;

DRUG RESEARCH; DRUG STRUCTURE; HYDROGEN BOND; PHYSICAL CHEMISTRY; PROTEIN BINDING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SOLVATION; X RAY DIFFRACTION;

COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; HUMANS; PHARMACEUTICAL PREPARATIONS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RESEARCH;

EID: 36549030345     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.08.004     Document Type: Review

References (35)

1. Fischer E. Einfluss der Configuration auf die Wirkung der Enzyme. Ber. Dtsch. Chem. Ges. 27 (1894) 2984-2993
2. Hansch C., et al. p-σ-π Analysis. A method for the correlation of biological activity and chemical structure. J. Am. Chem. Soc. 86 (1964) 1616-1626
3. Free S.M., et al. A mathematical contribution to structure-activity studies. J. Med. Chem. 7 (1964) 395-399
4. Norinder U. In silico modelling of ADMET-a mini review of work from 2000 to 2004. SAR QSAR Environ. Res. 16 (2005) 1-11
5. Martin Y.C. A bioavailability score. J. Med. Chem. 48 (2005) 3164-3170
6. Yoshida F., et al. QSAR model for drug human oral bioavailability. J. Med. Chem. 43 (2000) 2575-2585
7. Worth A.P., et al. The role of the European Chemicals Bureau in promoting the regulatory use of (Q)SAR methods. SAR QSAR Environ. Res. 18 (2007) 111-125
8. Cramer R.D., et al. Comparative molecular-field analysis (CoMFA) .1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc. 110 (1988) 5959-5967
9. Hopfinger A.J., et al. Construction of 3D-QSAR models using the 4D-QSAR analysis formalism. J. Am. Chem. Soc. 119 (1997) 10509-10524
10. Ekins S., et al. Three- and four-dimensional-quantitative structure activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab. Dispos. 28 (2000) 994-1002
11. Vedani A., et al. Multiple-conformation and protonation-state representation in 4D-QSAR: the neurokinin-1 receptor system. J. Med. Chem. 43 (2000) 4416-4427
12. Lukacova V., et al. Multimode ligand binding in receptor site modeling: implementation in CoMFA. J. Chem. Inf. Comput. Sci. 43 (2003) 2093-2105
13. Brzozowski A.M., et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997) 753-758
14. Todeschini R., et al. New molecular descriptors for 2D and 3D structures. Theory. J. Chemometrics 8 (1994) 263-272
15. Bravi G., et al. MS-WHIM, new 3D theoretical descriptors derived from molecular surface properties: a comparative 3D QSAR study in a series of steroids. J. Comput. Aided Mol. Des 11 (1997) 79-92
16. Silverman B.D., et al. Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition. J. Med. Chem. 39 (1996) 2129-2140
17. Pan D., et al. Quantitative structure-based design: formalism and application of receptor-dependent RD-4D-QSAR analysis to a set of glucose analogue inhibitors of glycogen phosphorylase. J. Chem. Inf. Comput. Sci. 43 (2003) 1591-1607
18. Vedani A., et al. 5D-QSAR: the key for simulating induced fit?. J. Med. Chem. 45 (2002) 2139-2149
19. Vedani A., et al. Combining protein modeling and 6D-QSAR. Simulating the binding of structurally diverse ligands to the estrogen receptor. J. Med. Chem. 48 (2005) 3700-3703
20. Lill M.A., et al. Raptor: combining dual-shell representation, induced-fit simulation, and hydrophobicity scoring in receptor modeling: application toward the simulation of structurally diverse ligand sets. J. Med. Chem. 47 (2004) 6174-6186
21. Lill M.A., et al. Combining 4D pharmacophore generation and multidimensional QSAR: modeling ligand binding to the bradykinin B2 receptor. J. Chem. Inf. Model. 46 (2006) 2135-2145
22. Lill M.A., et al. Prediction of small-molecule binding to cytochrome P450 3A4: flexible docking combined with multidimensional QSAR. Chem. Med. Chem. 1 (2006) 73-81
23. Teague S.J. Implications of protein flexibility for drug discovery. Nat. Rev. Drug Discov. 2 (2003) 527-541
24. Carlson H.A. Protein flexibility and drug design: how to hit a moving target. Curr. Opin. Chem. Biol. 6 (2002) 447-452
25. Zavodszky M.I., et al. Modeling correlated main-chain motions in proteins for flexible molecular recognition. Proteins 57 (2004) 243-261
26. Sousa S.F., et al. Protein-ligand docking: current status and future challenges. Proteins 65 (2006) 15-26
27. Mizutani M.Y., et al. Effective handling of induced-fit motion in flexible docking. Proteins 63 (2006) 878-891
28. Sherman W., et al. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 49 (2006) 534-553
29. Taylor N.R., et al. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B. J. Med. Chem. 41 (1998) 798-807
30. Vedani A., et al. Simulating alpha/beta Selectivity at the Human Thyroid Hormone Receptor: Consensus Scoring Using Multidimensional QSAR. Chem. Med. Chem. 2 (2007) 78-87
31. Dervarics M., et al. Development of a chirality-sensitive flexibility descriptor for 3 + 3D-QSAR. J. Chem. Inf. Model. 46 (2006) 1431-1438
32. Homans S.W. Probing the binding entropy of ligand-protein interactions by NMR. Chem. Bio. Chem. 6 (2005) 1585-1591
33. Overton C.E. Studien über die Narkose (1901), Gustav Fischer Verlag, Jena, Germany
34. DeLano W.L. The PyMOL Molecular Graphics System (2002), DeLano Scientific, Palo Alto, CA, USA
35. Vedani A., et al. A new force field for modeling metalloproteins. J. Am. Chem. Soc. 112 (1990) 4759-4767